Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on developing innovative therapies for hard-to-treat tumors and viruses. Their lead program, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance and eliminate the cardiotoxicity associated with traditional anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Beyond Annamycin, Moleculin is developing a pipeline of other therapeutic candidates, including WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and other cancers, and WP1122, an antimetabolite with potential for the treatment of viruses and certain cancer indications. The company is committed to conducting clinical trials to establish the safety and efficacy of their drug candidates and ultimately improve the lives of patients with serious diseases.

Moleculin Biotech is a clinical-stage pharmaceutical company focused on developing innovative therapies for hard-to-treat cancers and viral infections. Their primary focus is on advancing a pipeline of therapeutic candidates, particularly their lead program, Annamycin, a next-generation anthracycline designed to overcome multidrug resistance and cardiotoxicity associated with existing treatments. They are committed to improving the lives of patients by providing safer and more effective treatment options for diseases with limited therapeutic options.

Moleculin Biotech, Inc. fosters a culture of innovation, collaboration, and dedication to improving patient lives. They are a team of dedicated professionals driven by a shared commitment to developing new therapies for hard-to-treat cancers and viruses. They emphasize open communication, shared knowledge, and a willingness to embrace new ideas in their pursuit of groundbreaking treatments.